| Company | Exchange
| Symbol
| Last price
|
| Quote change
| Market cap
|
|
|
Qiagen NV
| NASDAQ
|
QGEN
|
18.69
|
|
+0.18
(0.97%)
| 4,374.00M
|
|
|
... life science research, genomics, gene-based drug discovery, nucleic acid-
based molecular diagnostics, genetic vaccination, and gene therapy markets.
| |
| |
|
|
Qiagen NV
| FRA
|
QIA
|
14.50
|
|
+0.05
(0.36%)
| 3,393.89M
|
|
|
... life science research, genomics, gene-based drug discovery, nucleic acid-
based molecular diagnostics, genetic vaccination, and gene therapy markets.
| |
| |
|
|
Qiagen NV
| ETR
|
QIA
|
14.51
|
|
+0.05
(0.31%)
| 3,394.59M
|
|
|
... life science research, genomics, gene-based drug discovery, nucleic acid-
based molecular diagnostics, genetic vaccination, and gene therapy markets.
| |
| |
|
|
Celanese Corporation
| NYSE
|
CE
|
49.68
|
|
+0.42
(0.85%)
| 7,931.48M
|
|
|
Celanese Corporation manufactures chemical products. The Company's portfolio
consists of five main businesses: Acetyl Products, Chemical Intermediates, ...
| |
| |
|
|
Momenta Pharmaceuticals, Inc.
| NASDAQ
|
MNTA
|
12.92
|
|
+0.05
(0.39%)
| 668.08M
|
|
|
Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company specializing
in the characterization and process engineering of complex molecules.
| |
| |
|
|
MOMENTA PHARMAC. DL-,0001
| FRA
|
LZ1
|
9.97
|
|
-0.03
(-0.30%)
|
|
|
|
|
|
|
CELANESE CORP. A DL-,0001
| FRA
|
DG3
|
38.03
|
|
-0.31
(-0.82%)
|
|
|
|
|
|
